

S5 Table. Patient characteristics of the matched cohort (chemotherapy alone vs. chemotherapy with TRT)

Characteristic	Chemotherapy alone (n=76)	Chemotherapy with ICI (n=38)	p-value	SMD
Age group (yr)			0.78	0.05
< 65	26 (34.2)	14 (36.8)		
≥ 65	50 (65.8)	24 (63.2)		
Sex			0.85	0.02
Female	11 (14.5)	6 (15.8)		
Male	65 (85.5)	32 (84.2)		
ECOG performance status			0.84	0.03
0-1	67 (88.2)	33 (86.8)		
2	9 (11.8)	5 (13.2)		
Smoking status			0.87	0.01
Never smoked	15 (19.7)	8 (21.1)		
Current or former smoker	61 (80.3)	30 (78.9)		
No. of involved extrathoracic sites			0.28	0.05
0-1	55 (72.4)	31 (81.6)		
≥ 2	21 (27.6)	7 (18.4)		
Brain metastasis at diagnosis			0.76	0.15
No	58 (76.3)	28 (73.7)		
Yes	18 (23.7)	10 (26.3)		
Bone metastasis at diagnosis			0.67	0.05
No	51 (67.1)	27 (71.1)		
Yes	25 (32.9)	11 (28.9)		
Liver metastasis at diagnosis			0.65	<0.001
No	68 (89.5)	35 (92.1)		
Yes	8 (10.5)	3 (7.9)		
Pleural metastasis at diagnosis			0.85	0.07
No	65 (85.5)	32 (84.2)		
Yes	11 (14.5)	6 (15.8)		
Follow-up duration (mo)			0.32	0.03
< 10	27 (35.5)	10 (26.3)		
≥ 10	49 (64.5)	28 (73.7)		
Response to 1st line systemic therapy ^{a)}			0.60	0.04
SD or PD	6 (7.9)	2 (5.3)		
PR or CR	70 (92.1)	36 (94.7)		

Values are presented as number (%). CR, complete response; ECOG, Eastern Cooperative Oncology Group; ICI, immune check inhibitor; PD, progressive disease; PR, partial response; SD, stable disease; SMD, standardized mean difference; TRT, thoracic radiation therapy. ^{a)}Median number of 1st line systemic therapy cycles was 6 (IQR, 4 to 6) in the chemotherapy alone group; 6 (IQR, 4 to 6) in the TRT group.